Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care $RHEL news 👇 Rediscover Health. newsfilecorp.com/release/315…

This is a big milestone! @toddmshapiro @FilamentHealth @rhelionLS Congrats

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care Full Story: nfne.ws/315164 #redlighttrip $RHEL.C #RHEL.CA #TRUFF #Cannabis #Marijuana #OTC

$RHEL: CSE / $TRUFF: OTC Rhelion Life Sciences / President of Filament Health speaking yesterday to the FDA. Very encouraging hearing. Grateful.

JUST IN: FDA holds major public hearing on psychedelic medicine, weighing how treatments like psilocybin & ibogaine could be safely approved and administered.

"From Underground to Mainstream" presenting some of our psychedelic learnings from years at @rhelionLS @FilamentHealth to FDA in the 2 min allotted.

Rhelion Life Sciences / Filament Health’s @Shashkes (Sarit Hashkes) speaking at the FDA’s psychedelic hearing today. 👏

Rhelion Life Sciences $RHEL / Filament Health’s President Sarit Hashkes will provide oral remarks at today’s FDA public hearing "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs". The full hearing will be streamed live on the FDA's youtube channel. youtube.com/live/5Kg1gj3KbAI… Sarit will be speaking around 3:40pm ET. newsfilecorp.com/release/314…

Proud and excited! @shashkes Sarit Hashkes is incredibly brilliant and highly respected in our sector. She is the perfect spokesperson on behalf of Rhelion and Filament Health in this very important conversation at the FDA’s Part 15 Hearing: “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs” this Monday. Filament Health’s patented, botanical psilocybin candidate PEX010 already supplies more than 80 academic research studies and compassionate-use programs worldwide. That real-world experience in regulated access, consistent supply, data and results are exactly the kind of practical insights we are so honored to share on considerations for potential future access. 🙏

Lots of amazing conversations and momentum around Ibogaine. Learn more about Filament Health’s IBEX011 $RHEL news: newsfilecorp.com/release/313…

$RHEL / $TRUFF News (Another first): Rhelion Life Sciences/Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurological Disorder The study is the first trial of PEX010 in a movement disorder and, to the Company's knowledge, the first anywhere to combine a psychedelic with physiotherapy. newsfilecorp.com/release/313…

A psychedelic compound best known for its effects on the brain may help prevent one of chemotherapy's most debilitating side effects—chemotherapy-induced peripheral neuropathy, researchers report in Science. In mouse models, as few as two doses of psilocybin given before treatment durably prevented CIPN through multiple cycles of chemotherapy, while preserving both nerve function and the therapies’ tumor-killing effects. 📄: scim.ag/4ctTNaF #SciencePerspective: scim.ag/466LJcj

JUST IN: Scientific study reveals psilocybin, the active compound in “magic mushrooms,” may help prevent painful nerve damage caused by chemotherapy.

Somewhere in the world today, someone is going to take some shrooms and... laugh harder than they have in years, hug their friends for no reason, and remember they like being alive. I love that.

Psilocybin as well. @RhelionLS @Filamenthealth’s PEX010 is in over 80 clinical trials and we have over 75 patents. Outliers VS outlaws. The grind is real but the impact and help provided even with the lengthy compliance/regulatory hurdles (much needed patience) can be a legacy. 🤔 I think you know something about patience, a regulatory process leading to legacy status!! Rhelion.com

newsfilecorp.com/release/312… $RHEL

Psilocybin physically repairs the brain by reversing cellular damage and restoring the growth of new neurons, research shows. For decades, major depressive disorder has been treated primarily with traditional antidepressants, which often take weeks to show results and fail to help millions of patients. However, a groundbreaking study published in Progress in Neuro-Psychopharmacology & Biological Psychiatry reveals that psilocybin, the active compound in 'magic mushrooms,' can physically reverse stress-induced brain damage. Lead researchers Agnieszka Bysiek and Krystyna Gołembiowska of the Polish Academy of Sciences demonstrated that just two low doses of psilocybin successfully reversed depressive behaviors and restored cellular growth in the brains of chronically stressed subjects. This study provides crucial preclinical evidence that the psychedelic compound directly repairs the neurological damage caused by chronic stress. The biological impacts of the treatment were profound, focusing on the hippocampus—the brain region critical for emotion and memory that normally shrinks under chronic stress. Psilocybin not only normalized stress hormones and restored brain-derived neurotrophic factor (BDNF) levels, but it also promoted the birth of brand-new neurons. This rapid and lasting physical rewiring allowed the subjects to overcome severe anxiety and recover their ability to experience pleasure. By directly stimulating neurogenesis and healing synaptic pathways, psilocybin shifts the paradigm of mental health treatment from merely managing symptoms to actively rebuilding the brain's circuitry. source: Bysiek, A., Szpręgiel, I., Wojtas, A., Maćkowiak, M., Wawrzczak-Bargieła, A., Leśkiewicz, M., Trojan, E., Kamińska, K., Kumorek, W., Bilecki, W., & Gołembiowska, K. (2026). Psilocybin restores behavioral and neuroplastic deficits induced by chronic stress in rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 147, 111710.

Notice “most popular” not “most successful” Give us back our Gods given rights Access to psychedelic medicine, spiritual guides, empathy bridges, and the ability to freely explore consciousness 🍄‍🟫 🧠 🌎

The world’s most popular antidepressant drugs are under fire go.nature.com/45OCpK7

Rumor is psilocybin could be approved by the FDA as early as January 2027